Table 3 First-line treatments and cardiac monitoring
Older patients (≥ 65) | Younger patients (< 65) | Overall | |
|---|---|---|---|
Patients, n | 1583 | 3821 | 5404 |
Number of patients initiating trastuzumab witha: | |||
Trastuzumab monotherapy | 372 (23%) | 637 (17%) | 1009 (19%) |
Taxane and taxane combinations: | 787 (50%) | 2368 (62%) | 3155 (58%) |
Endocrine therapy alone | 292 (18%) | 490 (13%) | 782 (14%) |
Vinorelbine | 19 (1%) | 60 (2%) | 79 (2%) |
Capecitabine | 40 (3%) | 58 (2%) | 98 (2%) |
Other chemotherapy combinations | 73 (5%) | 208 (5%) | 281 (5%) |
Patients with a baseline cardiac assessment, n | 782 (49%) | 1830 (48%) | 2612 (48%) |
Patients with a cardiac assessment while on trastuzumab, n | 956 (60%) | 2550 (67%) | 3506 (65%) |
Patients with a cardiac assessment at baseline and while on trastuzumab, n | 607 (38%) | 1519 (40%) | 2216 (39%) |
Number of cardiac assessments perpatient, median (IQR) | 4 (2–7) | 5 (2–8) | 4 (2–8) |